NeuroSense Therapeutics Ltd.
PrimeC
ALS, Alzheimer’s disease
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on PrimeC for ALS, Alzheimer’s disease is expected Date TBD.
Primary source
· SEC 6-K
verified 12h ago
“supporting the long-term development and potential commercialization of PrimeC in ALS, Alzheimer’s disease and additional neurodegenerative indications”